All In Biotech

Drug Trial Radar · NCT07669415

A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors

A Phase II,Open Label,Multicenter Study to Evaluate the Efficacy,Safety,and Tolerability of LM-168 Combined With Other Anti-tumor Therapies in Participants With Advanced Solid Tumor Trials

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

Jul 29, 2026

Primary completion

Dec 15, 2027

Study completion Dec 15, 2028

Sponsor

Lead sponsor
LaNova Medicines LimitedIndustry
Sponsor type
Industry
First posted
Jun 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For Safety introduction phase,this study is to evaluate the safety and tolerability of LM-168 in combination with other anti-tumor treatment regimens in participants of advanced solid tumor trials, determine the maximum tolerated dose (MTD), and explore the recommended phase II dose (RP2D). For Dose expansion phase,this study is to evaluate the preliminary antitumor activity of LM-168 in combination with other antitumor treatment regimens in participants of advanced solid tumor trials, measured by objective response rate (ORR)

Conditions

  • Advanced Solid Tumor

Interventions

  • LM-168Drug

    Q3W,Intravenous Drip

  • TislelizumabDrug

    Q3W,Intravenous Drip

  • Docetaxel injectionDrug

    Q3W,Intravenous Drip

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicity (DLT)Time frame: 78 Weeks
  2. Objective response rate (ORR)Time frame: From start of treatment to date of documented disease progression, up to approximately 42 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.